The second report from the National ALS Registry provides an updated estimate of the prevalence of amyotrophic lateral sclerosis in the U.S.
The ALS Registry Act, passed in 2008, authorized establishment of a National ALS Registry with the goals of defining amyotrophic lateral sclerosis (ALS) incidence and prevalence, characterizing ALS patients' demographics, and examining risk factors. The registry uses two sources of data: 80% derives from administrative data (from the Centers for Medicare and Medicaid Services, the Veterans Health Administration and the Veterans Benefits Administration) and 20% from a Web-based portal that patients with ALS can use for self-identification and enrollment. The registry excludes duplicates and uses a strict case definition based on ICD codes, death certificate data, and riluzole prescriptions. The registry administrators now report prevalence f…
Reviewing Author
DisclosuresGrant / Research supportNIH NeuroBioBank; ALS Association; NIH/National Institute of Neurological Disorders and Stroke; NIH/National Center for Advancing Translational Sciences; FDA; Department of Defense
Editorial boardsCochrane Collaboration
Leadership positions in professional societiesMuscle Study Group Executive Committee
DisclosuresGrant / Research supportNIH NeuroBioBank; ALS Association; NIH/National Institute of Neurological Disorders and Stroke; NIH/National Center for Advancing Translational Sciences; FDA; Department of Defense
Editorial boardsCochrane Collaboration
Leadership positions in professional societiesMuscle Study Group Executive Committee